Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew E Pink

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Journal of Psoriasis and Psoriatic Arthritis|December 1, 2025
Patient Experiences on the Diagnosis, Management, and Burden of Generalized Pustular Psoriasis: An International Web Survey and Qualitative Interview StudyMark Lebwohl, Hideki Fujita, Kilian Eyerich, et al.
Journal of the American Academy of Dermatology|November 16, 2024
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasisLaura K Ferris, Jerry Bagel, Yu-Huei Huang, et al.
Dermatology and Therapy|July 14, 2025
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)Jonathan I Silverberg, Melinda Gooderham, Norito Katoh, et al.
American Journal of Clinical Dermatology|September 8, 2023
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III TrialsEric L Simpson, Andrew E Pink, Andrew Blauvelt, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 15, 2022
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic DermatitisKristian Reich, Peter A Lio, Robert Bissonnette, et al.
Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD StudyJennifer Soung, Yong Cui, Robert Bissonnette, et al.
American Journal of Human Genetics|August 16, 2011
Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasisAlexandros Onoufriadis, Michael A Simpson, Andrew E Pink, et al.
Journal of the American Academy of Dermatology|March 25, 2026
Impact of early treatment of psoriasis on disease recurrence - Results from the STEPIn studyLars Iversen, Richard G Langley, Johann E Gudjonsson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 11, 2024
Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitisJonathan I Silverberg, Melinda Gooderham, Norito Katoh, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Journal of Psoriasis and Psoriatic Arthritis|December 1, 2025
Patient Experiences on the Diagnosis, Management, and Burden of Generalized Pustular Psoriasis: An International Web Survey and Qualitative Interview StudyMark Lebwohl, Hideki Fujita, Kilian Eyerich, et al.
Journal of the American Academy of Dermatology|November 16, 2024
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasisLaura K Ferris, Jerry Bagel, Yu-Huei Huang, et al.
Dermatology and Therapy|July 14, 2025
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)Jonathan I Silverberg, Melinda Gooderham, Norito Katoh, et al.
American Journal of Clinical Dermatology|September 8, 2023
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III TrialsEric L Simpson, Andrew E Pink, Andrew Blauvelt, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 15, 2022
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic DermatitisKristian Reich, Peter A Lio, Robert Bissonnette, et al.
Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD StudyJennifer Soung, Yong Cui, Robert Bissonnette, et al.
American Journal of Human Genetics|August 16, 2011
Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasisAlexandros Onoufriadis, Michael A Simpson, Andrew E Pink, et al.
Journal of the American Academy of Dermatology|March 25, 2026
Impact of early treatment of psoriasis on disease recurrence - Results from the STEPIn studyLars Iversen, Richard G Langley, Johann E Gudjonsson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 11, 2024
Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitisJonathan I Silverberg, Melinda Gooderham, Norito Katoh, et al.
Pageof 7